Identifying disease genes implicated in late-onset neurodegenerative disorders can be challenging due to the lack of DNA samples from multiple affected family members. To overcome this limitation, Smith et al. (2014) report in this issue of Neuron the first exome-wide rare variant analysis in unrelated familial amyotrophic lateral sclerosis (ALS) patients associating TUBA4A with ALS.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by impairment of both the upper motor neuron (UMN) and the lower motor neuron (LMN); its disease course is relentlessly progressive and most ALS patients die within a few years due to respiratory failure. Nonetheless, considerable clinical and genetic variability has been reported in ALS patients (Turner et al., 2013) . Linkage analyses in extended ALS families enabled the identification of genetic loci implicated in ALS and the discovery of several causal genes, including superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TARDBP), fused in sarcoma (FUS), and chromosome 9 open reading frame 72 (C9ORF72). The GGGGCC hexanucleotide repeat expansion in C9ORF72 is currently the most frequent genetic cause of ALS as well as frontotemporal dementia (FTD), a disease that is often reported as an accompanying feature in ALS patients and their affected relatives (DeJesus-Hernandez et al., 2011; Renton et al., 2011; van Blitterswijk et al., 2012a) . Based on pathological, clinical, and genetic similarities, ALS and FTD are now thought to represent a continuum of one broad neurodegenerative disorder (Ling et al., 2013) .
Recently, new technological developments accelerated the discovery of novel ALS and/or FTD-associated genes: using exome sequencing-a technique in which the coding regions of all genes are analyzed at once-a mutation in valosincontaining protein (VCP; p.R191Q) was identified in an ALS family (Johnson et al., 2010) . In two large ALS families, exome sequencing also revealed mutations in profilin 1 (PFN1; p.C71G and p.M114T) (Wu et al., 2012) . Additionally, exome sequencing led to the identification of matrin 3 mutations (MATR3; p.F115C) in a family with both ALS and FTD (Johnson et al., 2014) . In families with multisystem proteinopathy, exome sequencing revealed mutations in heterogeneous nuclear ribonucleoprotein A2B1 and A1 (hnRNPA2B1 and hnRNPA1; p.D290V and p.D262V) (Kim et al., 2013) . Follow-up experiments that assessed exome sequencing data of 212 familial ALS (FALS) patients subsequently resulted in the detection of one hnRNPA1 mutation (p.D262N), suggesting that this gene might also be involved in the pathogenesis of ALS. Importantly, while exome-sequencing was at the basis of these discoveries, each of these genes was discovered using a family-based genetic approach, and the variants identified cosegregated with disease. Follow-up experiments were subsequently performed to strengthen the original reports by the discovery of additional mutations and/or by supportive functional data. Other exome sequencing approaches have also been employed in ALS, including sequencing of ALS patients (n = 47) and both their unaffected parents in order to search for de novo mutations (Chesi et al., 2013) . This alternative approach revealed the presence of a mutation in neuronal chromatin remodeling complex component SS18L1 (also known as CREST; p.Q388stop). In summary, while the individual contribution of some of these novel genes to the genetic etiology of ALS may be relatively small, each of these discoveries has contributed to our current understanding of the causes of ALS and their underlying pathophysiological consequences.
Contrary to what would be expected by the tremendous progress made in recent years, the rapidly growing list of ALS genes is unable to explain the disease in approximately 50% of FALS patients and more than 90% of sporadic patients (SALS), suggesting that additional ALS genes must exist. In reality, however, most multigenerational ALS families available for research purposes have already been explained by mutations in one of the known genes, emphasizing the need for novel genetic approaches. To this end, a group of researchers headed by John Landers (Smith et al., 2014) now report a proof-of-principle study, which demonstrates that systematic sequencing of familial, but unrelated, ALS patients can also be fruitful in ALS. The group performed exome sequencing on a unique discovery cohort of 363 index FALS patients obtained through international collaborations and control data of 4,300 individuals (NHLBI's Exome Variant Server) and 31 internally sequenced samples. The size of their patient cohort is much larger than all previous exome sequencing studies in ALS and is particularly impressive given that less than 10% of ALS patients have a positive family history.
In the absence of family data, what strategy did Smith et al. (2014) employ to determine which of the thousands of novel or extremely rare genetic variants, bound to be present in each FALS patient, is relevant to ALS? Smith et al. (2014) performed a rare variant burden analysis, by comparing the frequency of genetic variants observed in each of 12,487 genes between the FALS patients and controls. The key to their success was in the use of strict filtering criteria, including only missense mutations predicted to be damaging by PolyPhen-2-a software tool that predicts possible impact of an amino acid substitution on the structure and function of a human protein-or mutations resulting in a gain or loss of a stop codon. They also only included mutations with a minor allele frequency less than 0.04% to remove potential noise from common or neutral variants masking true gene associations. While arbitrary, these criteria led Smith et al. (2014) to tubulin, Alpha 4A (TUBA4A), a component of microtubules, as their top hit and a potential novel ALS disease gene. This is particularly interesting in light of the recent discovery of mutations in PFN1 (by the same group) (Wu et al., 2012) , as profilins are one of the most important actin-binding proteins. After filtering, they identified four TUBA4A variants in ALS patients, whereas no damaging variants were present in control subjects (p = 9.1 3 10 À6 , P corrected = 0.09). When including benign variants, five nonsynonymous TUBA4A variants were detected in patients and three nonsynonymous TUBA4A variants in controls. Interestingly, all variants identified in ALS patients were located within a highly conserved region of TUBA4A encoded by exon 4. The group also obtained a replication cohort consisting of 272 index FALS cases and 5,510 internal controls, and those subjects were also sequenced for variants in exon 4 of TUBA4A. In this replication cohort, TUBA4A variants were found in two index cases (one of which did not segregate with disease) and two controls (both of which are predicted to be damaging; p = 1.5 3 10 À2 ). Importantly, a combined analysis of the discovery and replication cohorts led to a statistically significant overabundance of rare damaging variants in patients as compared to controls, even after correction for multiple testing (P corrected = 4.2 3 10 À3 ). Additional sequencing of the entire coding region in 1,355 sporadic ALS patients did not identify any mutations in exon 4, but it did reveal one mutation in exon 2 that was also present in one control subject and was predicted to be benign. Microtubules are composed of a heterodimer of a-and b-tubulin and are fundamental to neuronal morphogenesis and function. TUBA4A is one of multiple genes encoding an a-tubulin. Interestingly, mutations in at least seven other tubulin family members have been described to cause neurodevelopmental and neurodegenerative disorders (Tischfield et al., 2011) . Through a panel of in vitro assays, Smith et al. (2014) suggest that at least a subset of the TUBA4A variants identified in ALS patients disrupt microtubule dynamics and stability. Transient transfection of TUBA4A mutants in primary motor neurons and HEK293 cells revealed an inability to efficiently form a-/b-tubulin dimers in vitro and a decreased incorporation of some mutants into microtubules. Studies in COS7 cells also suggested that TUBA4A mutants inhibited microtubule network assembly and showed that expression of the mutants impaired the ability of endogenous TUBA4A protein to form microtubules, suggesting a dominant-negative disease mechanism. Finally, expression of at least one mutant (p.W407X) resulted in the formation of numerous small ubiquitinated cytoplasmic inclusions analogous to other ALS-associated mutations; however, since brain and spinal cord tissue of TUBA4A mutation carriers was not available for study, the relevance of these aggregates in vivo remains unclear.
The study led by John Landers identified a total of eight TUBA4A variants in ALS patients (six predicted damaging) and five variants in controls (two predicted damaging). One has to realize, though, that of the six potential damaging variants observed in patients, at least one did not segregate with disease (p.K430N) and another variant (p.A383T) was also present in an individual of African ancestry in one of the public databases studied. In fact, due to the lack of DNA samples from affected relatives, familial segregation with disease could only be demonstrated for two first-degree relatives carrying the p.T145P mutation and not for any of other TUBA4A mutations identified in this study. Moreover, in the absence of any recurrent mutation across ALS families, the selection of a representative mutation for in vivo modeling and characterization of its functional effect(s) is challenging. This points to the major limitation of a burden test as used in this study and underlines why it is important to be extremely careful in the interpretation of the effect on ALS risk for individual TUBA4A variants. While Smith et al. (2014) have clearly demonstrated that their approach can be valuable in identifying novel players in ALS disease, and potential novel therapeutic targets, no single TUBA4A variant to date can be considered pathogenic. Actually, it is likely that the effect of TUBA4A variants on ALS disease risk span a continuum from clearly pathogenic mutations, to mere ALS risk factors and even protective variants. While Smith et al. (2014) reported that no TUBA4A mutations were identified in 131 ALS samples with known mutations in ALS-associated genes, the current study also cannot rule out the possibility that the presence of (at least some of) these TUBA4A variants is insufficient to develop ALS on its own and that additional factors are needed to cause disease. This thought is particularly intriguing because ALS appears to arise from an interplay of many factors (e.g., genetic, developmental, environmental, and age related) (Turner et al., 2013) and evidence for an oligogenic basis of ALS has already been provided (van Blitterswijk et al., 2012b) .
In summary, follow-up studies will be required to elucidate the role of TUBA4A in the pathogenesis of ALS. Sequencing analysis of large numbers of additional FALS patients, SALS patients, and controls will be needed, not only to provide additional statistical support for a role of TUBA4A in ALS but also to systematically catalog TUBA4A variants, which will hopefully identify specific recurrent mutations in ALS patients. The role of TUBA4A in related disorders such as FTD also requires future study, especially since two of the mutation carriers were diagnosed with a combination of ALS and FTD (although they did carry variants predicted to be benign). Additional data mining of the exomes of the current and potentially even larger future cohorts of FALS patients, may also reveal additional ALS-associated genes. In this regard, it is important to mention that the strategy employed in the current study also revealed other strong candidates, including MATR3, recently identified as causative for ALS (Johnson et al., 2014) . There is no doubt that exome-and genome-wide rare variant analyses such as those described in this pioneering work from John Landers and his colleagues are going to drive the identification of novel ALS genes in the future. Translating these findings to disease risk for individual patients will however be a tremendous challenge and caution should be taken before any individual variant identified using this approach can be implicated in ALS.
While there is plenty of debate in the memory field, the classical view is that memory traces for events are laid down in cell ensembles across distributed hippocampal-cortical networks. The hippocampus is considered necessary, at least temporarily after encoding, for successful retrieval of these event memories via reinstatement of the patterns of activity within these cortical ensembles. According to this view, the hippocampus contains indices or pointers to cortical cell assemblies that collectively represent a given event (e.g., Eichenbaum, 2000) .
Observations of retrograde amnesia following hippocampal damage in human patients (such as H.M.), as well as in experimental animals, provide broad support for this view (Squire et al., 2004) . However, they tell little about how hippocampal and cortical cell ensembles interact to support memory retrieval. Two studies published in the current issue of Neuron, Cowansage et al. (2014) and Tanaka et al. (2014) , shed light on this interaction. Both studies used a genetic strategy to tag active cells at the time of memory encoding with light-sensitive opsins and then optogenetically manipulate the activity of these ''engram'' cells during retrieval.
In the first study, Tanaka et al. (2014) used a Fos-driven reporter mouse to tag active cells as mice learned an association between a shock and a context. The formation and maintenance of contextual fear memories engages distributed networks, and, as expected, training tagged ensembles of cells throughout the hippocampus and cortex. Usually, when mice return to the original training context, they exhibit conditioned fear responses, including freezing behavior, indicating that they recognize this as the place in which they previously received a shock. By expressing the inhibitory opsin (ArchT) in tagged cells in the CA1 region of the hippocampus, Tanaka et al. (2014) examined the impact of silencing engram cells
